Joint Formulary & PAD

Ruxolitinib - Vitiligo

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Cream
Associated Icons :
NFD1
NICE
Restrictions / Comments :

PAD Profile

ChemicalSubstance :
Ruxolitinib
Indication :
Vitiligo
Group Name :
Keywords :
skin, dermatology, repigmentation, skin colour,
Brand Names Include :
Opzelura
Important Information :
Latest Additions Date From :
01 Oct 2025
Latest Additions Date To :
31 Oct 2025
Guidelines :
Supporting Documents :
1

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee does not recommend the use of ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over in line with NICE TA1088.

A NON-FORMULARY traffic light status has been applied to ruxolitinib cream for this indication

Other Indications

Below are listed other indications that Ruxolitinib is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Vitiligo.

  • No records returned.